BI Asset Management Fondsmaeglerselskab A S Has $8.86 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 99,060 shares of the medical equipment provider's stock after purchasing an additional 7,043 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned 0.14% of Lantheus worth $8,862,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of LNTH. State of New Jersey Common Pension Fund D grew its holdings in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after buying an additional 115 shares during the period. Bleakley Financial Group LLC grew its stake in Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after acquiring an additional 129 shares during the period. Avantax Advisory Services Inc. increased its holdings in shares of Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares in the last quarter. Foundry Partners LLC raised its position in shares of Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Lantheus stock traded up $2.44 during mid-day trading on Thursday, reaching $103.64. The company's stock had a trading volume of 510,605 shares, compared to its average volume of 952,050. The business's 50 day simple moving average is $96.54 and its 200 day simple moving average is $95.40. Lantheus Holdings, Inc. has a 12 month low of $63.61 and a 12 month high of $126.89. The company has a market capitalization of $7.10 billion, a price-to-earnings ratio of 17.24 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.